z-logo
open-access-imgOpen Access
Wirelessly controlled, bioresorbable drug delivery device with active valves that exploit electrochemically triggered crevice corrosion
Author(s) -
Jahyun Koo,
Sung Bong Kim,
Yeon Sik Choi,
Zhaoqian Xie,
Amay J. Bandodkar,
Jawad M. Khalifeh,
Ying Yan,
Hojun Kim,
Maryam Kherad Pezhouh,
Karen Doty,
Geumbee Lee,
Yu-Yu Chen,
Seung Min Lee,
Dominic D’Andrea,
KiMin Jung,
KunHyuck Lee,
Kan Li,
Seongbin Jo,
Heling Wang,
Jae-Hwan Kim,
Jeonghyun Kim,
Sung-Geun Choi,
Woo Jin Jang,
Yong Suk Oh,
Inkyu Park,
Sung Soo Kwak,
JiHyeon Park,
Doosun Hong,
Xue Feng,
Chi Hwan Lee,
Anthony Banks,
Cecília Leal,
Hyuck Mo Lee,
Yonggang Huang,
Colin K. Franz,
Wilson Z. Ray,
Matthew R. MacEwan,
SeungKyun Kang,
John A. Rogers
Publication year - 2020
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.abb1093
Subject(s) - exploit , drug delivery , drug , crevice corrosion , corrosion , nanotechnology , biomedical engineering , materials science , computer science , medicine , pharmacology , metallurgy , computer security
Implantable drug release platforms that offer wirelessly programmable control over pharmacokinetics have potential in advanced treatment protocols for hormone imbalances, malignant cancers, diabetic conditions, and others. We present a system with this type of functionality in which the constituent materials undergo complete bioresorption to eliminate device load from the patient after completing the final stage of the release process. Here, bioresorbable polyanhydride reservoirs store drugs in defined reservoirs without leakage until wirelessly triggered valve structures open to allow release. These valves operate through an electrochemical mechanism of geometrically accelerated corrosion induced by passage of electrical current from a wireless, bioresorbable power-harvesting unit. Evaluations in cell cultures demonstrate the efficacy of this technology for the treatment of cancerous tissues by release of the drug doxorubicin. Complete in vivo studies of platforms with multiple, independently controlled release events in live-animal models illustrate capabilities for control of blood glucose levels by timed delivery of insulin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom